Clinical Trial Update: Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of tivozanib in combination with nivolumab in renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Tivozanib (tivozanib)
• nivolumab (nivolumab)

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Carcinoma, Renal Cell | Phase 1, Phase 2 | Status: COMPLETED